Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Himadri Speciality shares jump 6% to hit a 52-week high after a 38% rise in April amid focus on revenue growth - Mint
Himadri Speciality shares jump 6% to hit a 52-week high after a 38% rise in April amid focus on revenue growthMint
Himadri Speciality Q4 Results | Net profit surges 29% on higher revenue; declares dividend
Shares of Himadri Speciality Chemical Ltd ended at ₹537.50, up by ₹14.55, or 2.78%, on the BSE.
Stocks to Watch for April 24: Infosys, Tata Capital, LTM, Adani Energy Solutions, Cyient and more
Infosys, LTIMindtree, Tata Capital, Adani Energy Solutions, Cyient, Mahindra Logistics and Himadri Speciality Chemical post mixed Q4, key earnings from Reliance and others due April 24. Here are few stocks to keep an eye on ahead of Friday's trading session.
Stocks to buy for short term: Himadri Speciality, Sagility among 5 contra bets Ambareesh Baliga recommends buying now - Mint
Stocks to buy for short term: Himadri Speciality, Sagility among 5 contra bets Ambareesh Baliga recommends buying nowMint
Stocks to buy for short term: Himadri Speciality, Sagility among 5 contra bets Ambareesh Baliga recommends buying now
SEBI-registered market expert Ambareesh Baliga unveils five stock recommendations, including Shakti Pumps and Sagility, amid the ongoing US-Iran war. The stock picks are part of his contrarian investing strategy.
Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocks
The US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. Sun Pharma faces the steepest risk, while CDMOs like Sai Lifesciences may see selective impact. Analysts at Jefferies and Nomura expect modest to mid-single-digit earnings pressure.
Speciality Medicines IPO opens: Issue booked 15% so far; check GMP, price band and other key details about SME IPO
Speciality Medicines IPO Day 1: Speciality Medicines IPO, worth ₹29 crore, opened for bidding today and will available till March 24. The offer is entirely a fresh share sale. Speciality Medicines IPO GMP remains nil.
Ambuja Neotia Group to develop over Rs 700 cr integrated healthcare and hospitality project in Guwahati
Ambuja Neotia Group will build a large integrated healthcare and hospitality project in Guwahati. The Rs 700 crore investment will include a 300-bed multi-speciality hospital and a 4+ star hotel. This initiative aims to boost the region's healthcare infrastructure and economy. The project is expected to create thousands of jobs. It marks the group's second healthcare venture in Assam.
HMEL to invest Rs 2,600 cr in speciality, fine chemicals sector in Punjab: LN Mittal
HPCL-Mittal Energy Limited (HMEL) announced a Rs 2,600 crore investment in Punjab's speciality and fine chemicals sector. Additionally, HMEL plans to launch 500 new retail fuel outlets nationwide, equipped with modern technology. This expansion follows HMEL's significant Rs 60,000 crore investment in its Bathinda refinery, Punjab's sole oil refinery.
Balaji Amines' plants closed as West Asia war hits ammonia supply
The speciality chemicals maker said some of its plants have become non-operational due to disruptions in the supply of ammonia, a key raw material, with certain key suppliers invoking the force majeure clause. Shares of Balaji Amines Ltd ended at ₹1,047.55, up by ₹4.85, or 0.47%, on the BSE today, March 12.
Novo Holdings scales up India bets with bigger cheques, focus on mature healthcare assets
The life sciences investor is increasing ticket sizes and doubling down on speciality care and healthcare services as India emerges as a key deployment market in Asia.
Anupam Rasayan completes USD150-mln acquisition of US speciality chemical maker Jayhawk
Anupam Rasayan India has acquired US-based Jayhawk Fine Chemicals Corporation for approximately USD 150 million. This strategic move aims to broaden Anupam Rasayan's global presence and access new end-use markets. The acquisition is expected to enhance its integrated platform and create cross-selling opportunities. Jayhawk's operations in performance materials will now be consolidated into Anupam Rasayan's financials.